253 related articles for article (PubMed ID: 23924821)
1. Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function.
Shan YQ; Zhu YP; Pang J; Wang YX; Song DQ; Kong WJ; Jiang JD
Biol Pharm Bull; 2013; 36(10):1562-9. PubMed ID: 23924821
[TBL] [Abstract][Full Text] [Related]
2. Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein efflux.
Shan YQ; Ren G; Wang YX; Pang J; Zhao ZY; Yao J; You XF; Si SY; Song DQ; Kong WJ; Jiang JD
Metabolism; 2013 Mar; 62(3):446-56. PubMed ID: 23079743
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of Berberine Hypoglycemic Activity by Oligomeric Proanthocyanidins.
Zhang H; Wang X; Wang T; Chen K; Wang H; Jia Q; Li Y
Molecules; 2018 Dec; 23(12):. PubMed ID: 30558158
[TBL] [Abstract][Full Text] [Related]
4. Improvement of intestinal transport, absorption and anti-diabetic efficacy of berberine by using Gelucire44/14: In vitro, in situ and in vivo studies.
Sun J; Bao H; Peng Y; Zhang H; Sun Y; Qi J; Zhang H; Gao Y
Int J Pharm; 2018 Jun; 544(1):46-54. PubMed ID: 29654898
[TBL] [Abstract][Full Text] [Related]
5. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells.
Fu LW; Zhang YM; Liang YJ; Yang XP; Pan QC
Eur J Cancer; 2002 Feb; 38(3):418-26. PubMed ID: 11818209
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of P-glycoprotein by HIV protease inhibitors increases intracellular accumulation of berberine in murine and human macrophages.
Zha W; Wang G; Xu W; Liu X; Wang Y; Zha BS; Shi J; Zhao Q; Gerk PM; Studer E; Hylemon PB; Pandak WM; Zhou H
PLoS One; 2013; 8(1):e54349. PubMed ID: 23372711
[TBL] [Abstract][Full Text] [Related]
7. Nanoemulsion improves hypoglycemic efficacy of berberine by overcoming its gastrointestinal challenge.
Xu HY; Liu CS; Huang CL; Chen L; Zheng YR; Huang SH; Long XY
Colloids Surf B Biointerfaces; 2019 Sep; 181():927-934. PubMed ID: 31382342
[TBL] [Abstract][Full Text] [Related]
8. Drug-drug interactions between ketoconazole and berberine in rats: pharmacokinetic effects benefit pharmacodynamic synergism.
Zhou Y; He P; Liu A; Zhang L; Liu Y; Dai R
Phytother Res; 2012 May; 26(5):772-7. PubMed ID: 22114028
[TBL] [Abstract][Full Text] [Related]
9. Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.
Li C; Choi DH; Choi JS
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):99-108. PubMed ID: 22210483
[TBL] [Abstract][Full Text] [Related]
10. Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp.
Qiu W; Jiang XH; Liu CX; Ju Y; Jin JX
Phytother Res; 2009 Nov; 23(11):1553-8. PubMed ID: 19370549
[TBL] [Abstract][Full Text] [Related]
11. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine.
Choi JS; Choi I; Choi DH
Pharmacol Rep; 2013; 65(5):1422-30. PubMed ID: 24399740
[TBL] [Abstract][Full Text] [Related]
12. MgAl monolayer hydrotalcite increases the hypoglycemic effect of berberine by enhancing its oral bioavailability.
Wang A; Yang W; Yang X; Mei X; Hu T; Liang R; Meng D; Yan D
Biomed Pharmacother; 2020 Jul; 127():110140. PubMed ID: 32380387
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interactions between metformin and berberine in rats: Role of oral administration sequences and microbiota.
Lyu Y; Zhang Y; Yang M; Lin L; Yang X; Cheung SCK; Shaw PC; Chan PKS; Kong APS; Zuo Z
Life Sci; 2019 Oct; 235():116818. PubMed ID: 31473193
[TBL] [Abstract][Full Text] [Related]
14. Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles.
Xue M; Yang MX; Zhang W; Li XM; Gao DH; Ou ZM; Li ZP; Liu SH; Li XJ; Yang SY
Int J Nanomedicine; 2013; 8():4677-87. PubMed ID: 24353417
[TBL] [Abstract][Full Text] [Related]
15. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.
Pirillo A; Catapano AL
Atherosclerosis; 2015 Dec; 243(2):449-61. PubMed ID: 26520899
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Modulation of Glibenclamide Transport by P-glycoprotein Inhibitory Antidiabetic African Plant Extracts.
Ezuruike UF; Chieli E; Prieto JM
Planta Med; 2019 Aug; 85(11-12):987-996. PubMed ID: 31350736
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin.
Lee CK; Ki SH; Choi JS
Biopharm Drug Dispos; 2011 May; 32(4):245-51. PubMed ID: 21506134
[TBL] [Abstract][Full Text] [Related]
18. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression.
Kong WJ; Zhang H; Song DQ; Xue R; Zhao W; Wei J; Wang YM; Shan N; Zhou ZX; Yang P; You XF; Li ZR; Si SY; Zhao LX; Pan HN; Jiang JD
Metabolism; 2009 Jan; 58(1):109-19. PubMed ID: 19059538
[TBL] [Abstract][Full Text] [Related]
19. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.
Choi SJ; Shin SC; Choi JS
Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815
[TBL] [Abstract][Full Text] [Related]
20. Dual-functional Brij-S20-modified nanocrystal formulation enhances the intestinal transport and oral bioavailability of berberine.
Xiong W; Sang W; Linghu KG; Zhong ZF; Cheang WS; Li J; Hu YJ; Yu H; Wang YT
Int J Nanomedicine; 2018; 13():3781-3793. PubMed ID: 29988733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
